Table 1. Key characteristics of the included studies

Study ID / Entrance Criteria / Comparison / Duration of Treatment/Follow up / Sample Size in each group / Age
Mean
(SD) in each group / Female, n (%) in each group / Outcomes
Alessandria 2007 [18]; Italy / Cirrhosis, renal failure and HRS Type I or II (IAC criteria) / Noradrenaline (max 0.7 ug/kg/min) v. Terlipressin (2mg IV q4hrs) / 2 weeks/Till death or liver transplantation / 10; 12 / 56(3);
55 (2) / 3 (33.3); 3(25) / Completea HRS reversal; Mortality; HRS recurrenceb
Boyer 2016 [19]; USA and Canada / Cirrhosis, ascites and HRS type I (IAC criteria) / Terlipressin(1 mg IV q6hrs) and albumin(20 to 40 g IV per day) v.albumin (20-40 g IV per day) / 14 days/90 days / 97; 99 / 55.8 (84); 54.8 (8.5) / 45 (46.4); 32 (32.3) / Completea HRS reversal; Mortality; Adverse events
Cavallin 2015 [20]; Italy / Cirrhosis, HRS type I or II (IAC criteria) / TerlipressinIV infusion (max 12 mg/24 hours) with IV albumin (max 20-40 g/day thereafter) v. midodrine (max 12.5 mgthrice daily) with octreotide (max 200 mcg thrice daily) and albumin (max 20-40 g/day) / 14 days/3 months / 27; 21 / 60 (12); 65 (10) / 6 (22.2); 10 (47.6) / Completea and partialc HRS reversal; Mortality; Adverse events; Cardiovascular adverse events
Cavallin 2016 [21]; Italy / Cirrhosis, HRS type I (IAC criteria) / Terlipressin(0.5 mg q4hrs to a max of 12 mg/day IV bolus) with Albumin (max 20 to 40 g/day IV) v. Terlipressin (continuous infusion to a max of 12 mg/day) with Albumin(max 20 to 40 g/day IV) / 15 days/3 months / 37; 34 / 59.4 (8.9); 57.4 (10.5) / 13 (35.1); 10 (29.4) / Completea and partialc HRS reversal; Mortality; adverse events and cardiovascular adverse events
Ghosh 2013 [22]; India / Cirrhosis,ascites, HRS type II / Noradrenaline (max 3 mg/h IV) with albumin infusion (20 g/day IV) v.Terlipressin (max 2 mg Q6h IV) with albumin infusion (20 g/day IV) / 15 days/3 months / 23; 23 / 48.2 (10.5); 45.8 (9.2) / 7 (30.4); 3 (13.1) / Completea HRS reversal; Mortality; Cardiovascular adverse events and adverse events
Indrabi 2013 [23]; India; Conference abstract / Cirrhotics with type 1 HRS / Noradrenaline with albumin infusion v. Terlipressin with albumin infusion (Details regarding dosage regimen are absent) / No mention about duration of therapy but followed up for 90 days. / No details / No details / No details / Complete HRS reversal; Mortality and recurrence of HRS. Details on the definition of complete reversal and recurrence of HRS are absent.
Martin-Llahi 2008 [24]; Spain / Cirrhosis, HRS type I or II / Terlipressin(max 2 mg IV q4h)with albumin (max 40 g/day IV) / 15 days/3 months / 23;23 / 59 (10);
55 (11) / 7 (30.4); 10 (43.5) / Completea and partialc HRS reversal; Mortality; adverse events and cardiovascular adverse events
Neri 2008 [25]; Italy / Cirrhosis,HRS type I (IAC criteria). / Terlipressin (max 1 mg q8hrs IV) with albumin (max 20 to 40 g/day IV) v. albumin (max 20-40 g/day IV) / 2 weeks/3 months / 26; 26 / 59 (4); 60 (3) / 16 (61.6); 5 (19.2) / Completea and partialc HRS reversal; Mortality
Pomier-Layrargues 2003 [26]; Canada / Cirrhosis, HRS type I or II (IAC criteria). / Octreotide (50 mcg/h infusion) with albumin (50 g/day IV). / 4 days/70 days / 7; 9 / 53.9 (1.9); 50.8 (32) / 2 (28.6); 2 (22.2) / Partiald HRS; Improved renal function
Sanyal 2008 [27]; USA, Germany and Russia / Acute or chronic liver disease, HRS type I (IAC criteria). / Terlipressin (1 mg q6h) with albumin (100 g on day 1 and 25 g/day subsequently IV) v. albumin (100 g on day 1 and 25 g/day subsequently IV). / 14 days/6 months / 56; 56 / 50.6 (10.5); 52.9 (11.4) / 15 (26.8); 17 (30.4) / Completea and partialc HRS reversal; Mortality; adverse events; HRS recurrenceb
Sharma 2008 [28]; India / Cirrhosis, HRS type I (IAC criteria) / Noradrenaline (max 3 mg/h infusion) with albumin (max 20-40 g/day IV) v. Terlipressin (max 2 mg q6h IV) with albumin (max 20-40 g/day IV). / 15 days/15 days / 20; 20 / 48.2 (13.4); 47.8 (9.8) / 3 (15); 3 (15) / Completea and partialc HRS reversal; Mortality; adverse events; cardiovascular adverse events; HRS recurrenceb
Singh 2012 [29]; India / Cirrhosis, HRS type I / Terlipressin (max to 2 mg q6h IV) with albumin (20-40 g/day IV) v. Noradrenaline (max 3 mg/h) with albumin (20-40 g/day IV). / 15 days/30 days / 23; 23 / 51.4 (11.6); 48.3 (11.6) / 4 (17.4); 4 (17.4) / Completea HRS reversal; Mortality; adverse events
Solanki 2003 [30]; India / Cirrhosis, HRS type I (IAC criteria) / Terlipressin (max 1 mg q12h) with albumin (20 g/day IV) v. Albumin (20 g/day IV) / 15 days/15 days / 12; 12 / 51 (5); 52 (4.8) / 3 (25); 4 (33.3) / Mortality
Srivastava 2015 [31]; India / Cirrhosis, ascites, HRS type I or II (IAC criteria). / Terlipressin (0.5 mg every 6 hourly) with albumin (20 g/day IV) v. Dopamine (2 mcg/kg/min IV with fructose 0.01 mg/kg/h) with albumin (20 g/day IV). / 5 days/30 days / 40; 40 / 45.8 (13.9); 39.2 (9.6) / 4 (10); 7 (17.5) / Mortality; Adverse events and cardiovascular adverse events
Tavakkoli 2011 [32]; Iran / Cirrhosis, HRS / Noradrenaline infusion (0.1-0.7 mcg/kg/min IV) with albumin (20 g/day IV) v. Octreotide (max 200 mcg S.C thrice daily) with midodrine (max 15 mg thrice daily) with albumin (20 g/day IV). / 15 days/3 months / 11; 12 / 52 (12.95); 52.9 (12.6) / 4 (36.4); 4 (33.3) / Completea HRS reversal; Mortality; HRS recurrence
Zafar 2012 [33]; Pakistan; Conference abstract / Cirrhosis, HRS / Terlipressin(1 mg q4h IV) with albumin (max 40 g/day IV) v. albumin (max 40 g/day IV). / 7-10 days/3 months / No details / No details / No details / Improved renal function and mortality

HRS – Hepatorenal syndrome; IAC – International Ascites Club; a – Complete reversal as defined by reduction in serum creatinine to a final value of 1.5 mg/dl (133 micromol/L); b – Recurrence was defined as increase in serum creatinine by more than 50% with respect to the lowest value in patients with complete response and with a final value > 1.5 mg/dl; c – Partial response as defined by > 50% reduction in serum creatinine compared to baseline but the final value exceeds 1.5 mg/dl (133 micromol/L).; d – Response was defined by reduction of at least 20% in the serum creatinine value compared to baseline.